Literature DB >> 17258463

Design and synthesis of pyridine-pyrazolopyridine-based inhibitors of protein kinase B/Akt.

Gui-Dong Zhu1, Jianchun Gong, Viraj B Gandhi, Keith Woods, Yan Luo, Xuesong Liu, Ran Guan, Vered Klinghofer, Eric F Johnson, Vincent S Stoll, Mulugeta Mamo, Qun Li, Saul H Rosenberg, Vincent L Giranda.   

Abstract

Thr-211 is one of three different amino acid residues in the kinase domain of protein kinase B/Akt as compared to protein kinase A (PKA), a closely related analog in the same AGC family. In an attempt to improve the potency and selectivity of our indazole-pyridine series of Akt inhibitors over PKA, efforts have focused on the incorporation of a chemical functionality to interact with the hydroxy group of Thr-211. Several substituents including an oxygen anion, amino, and nitro groups have been introduced at the C-6 position of the indazole scaffold, leading to a significant drop in Akt potency. Incorporation of a nitrogen atom into the phenyl ring at the same position (i.e., 9f) maintained the Akt activity and, in some cases, improved the selectivity over PKA. The structure-activity relationships of the new pyridine-pyrazolopyridine series of Akt inhibitors and their structural features when bound to PKA are also discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17258463     DOI: 10.1016/j.bmc.2007.01.010

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  5 in total

1.  Stacking with No Planarity?

Authors:  Hakan Gunaydin; Michael D Bartberger
Journal:  ACS Med Chem Lett       Date:  2016-04-06       Impact factor: 4.345

2.  Combining ligand- and structure-based in silico methods for the identification of natural product-based inhibitors of Akt1.

Authors:  Priya Mahajan; Bhumika Wadhwa; Manas Ranjan Barik; Fayaz Malik; Amit Nargotra
Journal:  Mol Divers       Date:  2019-02-23       Impact factor: 2.943

3.  Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt).

Authors:  Tatiana McHardy; John J Caldwell; Kwai-Ming Cheung; Lisa J Hunter; Kevin Taylor; Martin Rowlands; Ruth Ruddle; Alan Henley; Alexis de Haven Brandon; Melanie Valenti; Thomas G Davies; Lynsey Fazal; Lisa Seavers; Florence I Raynaud; Suzanne A Eccles; G Wynne Aherne; Michelle D Garrett; Ian Collins
Journal:  J Med Chem       Date:  2010-03-11       Impact factor: 7.446

4.  Elucidation of binding mode and three dimensional quantitative structure-activity relationship studies of a novel series of protein kinase B/Akt inhibitors.

Authors:  M Muddassar; F A Pasha; M M Neaz; Y Saleem; S J Cho
Journal:  J Mol Model       Date:  2008-11-29       Impact factor: 1.810

5.  Synthesis and antimicrobial activity of some new pyrazoles, fused pyrazolo[3,4-d]-pyrimidine and 1,2-dihydroimidazo-[2,1-c][1,2,4]triazin-6-one derivatives.

Authors:  Sobhi Mohamed Gomha; Huwaida M E Hassaneen
Journal:  Molecules       Date:  2011-08-04       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.